ATC code none PubChem CID 11960529 DrugBank DB07232 Molar mass 244.29 g/mol ChEMBL ID 506871 IUPHAR/BP 7417 | Legal status experimental IUPHAR/BPS 7417 UNII 01O4K0631N Pubchem 11960529 ChemSpider ID 10134775 | |
 | ||
Combination of veliparib and chemotherapy in brca positive breast cancer
Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.
Contents
- Combination of veliparib and chemotherapy in brca positive breast cancer
- Dr garcia on a trial analyzing the parp inhibitor veliparib
- Development
- Clinical trials
- References
Dr garcia on a trial analyzing the parp inhibitor veliparib
Development
Veliparib is being developed by AbbVie. It was derived from a prior lead compound (A 620223). The FDA awarded orphan drug status in November 2016 for NSCLC.
Clinical trials
As of 2017, 96 clinical trials involving veliparib had been registered with the FDA. It was included in the I-SPY2 breast cancer trial.
Numerous phase I clinical trials are in progress. Over 40 phase II clinical trials have been registered, for indications such as metastatic melanoma, breast cancer, NSCLC, prostate cancer and brain tumors associated with metastatic primary tumors.
Combination trials have evaluated velibarib in combination with doxorubicin, temozolomide, topotecan, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, gemcitabine, and others.
By June 2014 it was in three phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC).